Post-Operative Measures for the Subtle Neurocancers

Dr. Toru Ouchi*

Roswell Park Cancer Institute USA

*Corresponding Author:
Dr. Toru Ouchi
Roswell Park Cancer Institute USA
 
Visit for more related articles at Neuro-Oncology: Open Access

Advancement in a technology is always dedicated for the wellbeing of the globe in specific human beings. Currently published Volume 2, Issue 1 articles from different continents and is methodically addressing the various problems faced by mankind of modern era.

Impact of the brain tumor treatment on quality of life in children’s had been reported by Singh et al. The reported incidence of child brain tumors has been on rise over the decades, mainly due to improved diagnostics facilities. The need for a long term monitoring and follow-up to maintain psychological homeostasis care continues to grow and even limited studies are available, which canintervene to enhance the quality of life of individuals affected by the brain tumor. The journal exposes the major gaps in this area and appeals for further investigation on many aspects [1].

(No mention of the author) investigated the patients who underwent single brain metastasis surgical resection followed by field radiation therapy; local recurrence (LR) free survival, distant failure (DF) free survival and overall survival (OS) were estimated and correlated with clinical variables. The study outcomes suggest that localized field radiation therapy after surgical excision of brain metastasis in selected patients has acceptable local control rates and toxicity [2].

Review article (Written by whom?) on BRAT1 in Brain Function pedantically reveals the role of BRAT1 (BRCA1- associated ATM activator-1) gene, which is involved in the cell proliferation and migration, mTOR signaling, DNA repair, mitochondrial homeostasis and apoptosis. An article aftermath suggests that the loss of BRAT1 expression and function due to mutations justifies this brain atrophy and its consequences. Further extended researches may result in the new therapeutic options for this syndrome and perhaps for cancer treatment too [3].

(Mention the name) ’s efforts to conduct retrospective review of patients and nine charts were reviewed; valuable information obtained have been included as estreatment regimen, tumor type, side effects and management. Findings state that temozolomide has been proven to be an effective drug of choice in embryonal tumors and combination with CSI has been tolerable with side effects mainly consisting of myelosuppression, further which is treatable and reversible [4].

References

Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Recommended Conferences

Flyer image
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh